CAMAGÜEY.-Based on the safety and immunogenicity results recorded in clinical trials and intervention studies with Soberana 02 and Abdala, the Center for State Control of Medicines, Medical Equipment and Devices (CECMED) approved a health intervention with these vaccine candidates.

In Camagüey, the intervention with Abdala included a universe of 37,880 participants. 37,827 received the first dose, among them health personnel, students and professors of Medical Sciences and risk groups for their work in close relationship with the Red Zones in hospitals and isolation centers.

Dr. Sonia María González Vega, head of the primary care section, principal investigator of the process in the territory, assured that “the process is progressing satisfactorily in the municipalities. Those who have received Abdala express their gratitude at all times. Their greater security and tranquility when entering risk areas shows their confidence in the Cuban vaccine ”.

As of May 28, around 21,000 people had received the second dose, more than 55% of the universe.

The specialist also pointed out that the conditions for the intervention are being prepared for the entire population scheduled for the month of June and that "it will begin with those over 60 years of age as an identified risk group."

For the administration of the drug, a total of 42 vaccination sites and 51 temprorary vaccination sites were enabled in the province. Among the exclusion criteria is having recently suffered from COVID-19, receiving some type of immunomodulators or immunosuppressants, allergy to thimerosal or aluminum, and pregnant or in the puerperium and lactation stages.

According to the Minister of Public Health, José Ángel Portal Miranda, it is expected that by June 22 percent of the Cuban population will be immunized against COVID-19 and in August it will reach 70%.

Translated by Linet Acuña Quilez